Study of SNV4818 for advanced solid tumors with PIK3CA mutation
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug, SNV4818, for people with advanced solid tumors that have a specific change in the PIK3CA gene. It may help when other treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have an advanced or metastatic solid tumor with a change in the PIK3CA gene.
- Your tumor has not responded to or you cannot tolerate other available treatments.
- Your tumor can be measured on scans or through blood tests.
- You must be able to do your daily activities with little or no help (ECOG score 0 or 1).
- You cannot have uncontrolled diabetes, active brain tumors, or serious heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called ETX-636 in people whose cancer has a specific gene change (PIK3CA mutation) and has not responded to at least one prior treatment. The goal is to see if the drug can shrink tumors or stop them from growing.
This trial tests tersolisib, a new targeted medicine, in adults with advanced or hard-to-remove solid cancers. It focuses on tumors that have a specific genetic change (PI3Kα mutation) to see how well the treatment works and what side effects it causes.
This trial tests whether a new targeted pill (inavolisib) plus hormone therapy (fulvestrant) can slow or stop breast cancer growth in people whose cancer has a specific genetic change called a PIK3CA mutation. It is for patients whose disease worsened after previous hormone-and-CDK-inhibitor treatment.
This trial tests an experimental drug called K-1728 in people with advanced solid tumors that have a specific genetic change called PIK3CA. The goal is to see if the drug can shrink tumors or slow their growth.
This study tests a new drug called LAE118, which targets cancers with a specific gene change called PIK3CA. The drug is given alone or with other treatments for advanced solid tumors, and the goal is to see if it is safe and can help shrink tumors.
This trial tests a new pill (CGT6297) that targets cancer cells with a specific PIK3CA gene change. It may be an option for people with certain advanced solid tumors, including endometrial or breast cancer, after standard treatments have stopped working.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.